Kymab Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Kymab Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH263420D
  • |
  • Pages: 29
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Kymab Ltd (Kymab) is a therapeutic antibody company that discovers and develops fully human monoclonal antibody drugs. The company offers pipepline of assets in the therapeutic areas of immuno-oncology, inflammatory disease, haematology, and infectious diseases. Its products pipeline includes KY1003-Anti PD-L1, KY1006-Anti-LIGHT, KY1005-Anti-OX40L, KV7005, KY1041, KY1040, KY1036, KY1034, KY1020, and others. Kymab utilizes kymouse antibody, a transgenic mouse technology platform to generate human antibodies against disease targets. The company's pipeline treats various diseases including immunology, chronic anemia, chronic pain, dyslipidemia, infectious diseases, immune-oncology, ebola, and orphan oncology, and others. It also offers pre-clinical and clinical development services. The company collaborates with pharmaceutical, biotechnology and academic partners to discover, develop and commercialize monoclonal antibodies in various therapeutic areas. Kymab is headquartered in Cambridge, the UK.

Kymab Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

List of Tables

List of Figures

Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Kymab Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Kymab Ltd, Medical Devices Deals, 2012 to YTD 2018

Kymab Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Kymab Ltd, Pharmaceuticals & Healthcare, Deal Details

Venture Financing

Kymab Raises USD100.5 Million in Series C Financing

Kymab Raises Additional USD50 Million in Series B Financing

Kymab Raises USD40 Million in Series B Financing

Partnerships

Heptares Therapeutics to Form Partnership with Kymab

Kymab Enters into Agreement with University of Texas MD Anderson

Kymab Enters into Partnership Agreement with Dr Stephen Gillies

Licensing Agreements

EpimAb Biotherapeutics Enters into Licensing Agreement with Kymab

Novo Nordisk Enters Into Licensing Agreement With Kymab For Kymouse

Kymab Ltd-Key Competitors

Kymab Ltd-Key Employees

Kymab Ltd-Locations And Subsidiaries

Head Office

Recent Developments

Corporate Communications

May 09, 2017: Kymab Group appoints chief medical officer

May 09, 2017: Sonia Quaratino appointed Kymab CMO

Jan 23, 2017: Kymab appoints Dr Arndt Schottelius as Executive Vice President Research & Development

Government and Public Interest

Jan 09, 2017: Kymab expands Infectious Disease Programmes

Clinical Trials

Jul 31, 2017: Kymab's KY1005 Antibody in Clinical Trial

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer

List of Figures

Kymab Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Kymab Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Kymab Ltd, Medical Devices Deals, 2012 to YTD 2018

List of Tables

Kymab Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016

Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Kymab Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Kymab Ltd, Deals By Therapy Area, 2012 to YTD 2018

Kymab Ltd, Medical Devices Deals, 2012 to YTD 2018

Kymab Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Kymab Raises USD100.5 Million in Series C Financing

Kymab Raises Additional USD50 Million in Series B Financing

Kymab Raises USD40 Million in Series B Financing

Heptares Therapeutics to Form Partnership with Kymab

Kymab Enters into Agreement with University of Texas MD Anderson

Kymab Enters into Partnership Agreement with Dr Stephen Gillies

EpimAb Biotherapeutics Enters into Licensing Agreement with Kymab

Novo Nordisk Enters Into Licensing Agreement With Kymab For Kymouse

Kymab Ltd, Key Competitors

Kymab Ltd, Key Employees

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license

Single User License
USD 250 INR 16863
Site License
USD 500 INR 33725
Corporate User License
USD 750 INR 50588

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com